Posttraumatic stress disorder (PTSD) is associated with a reduced ratio of naïve cytotoxic T lymphocytes, an increased ratio of memory cytotoxic T lymphocytes, and a reduced proportion of FoxP3 þ regulatory T lymphocytes. This study investigated whether these immunological alterations are reversible through an evidence based psychotherapeutic treatment. Therefore, 34 individuals with PTSD were randomly assigned to either a treatment condition of 12 sessions narrative exposure therapy (NET) or a waitlist control (WLC) group. PTSD symptoms were significantly reduced in the NET group, but not in the WLC group, four months post therapy (effect size: Hedges' g ¼ 1.61). One year after therapy, PTSD symptoms were improved even further in the NET group compared to baseline (Hedges' g ¼ 1.96). This symptom improvement was mirrored in an increase in the originally reduced proportion of regulatory T cells (T regs ) in the NET group at the one year follow up, when comparing subgroups matched for baseline T reg numbers. However, no changes were found for the initially reduced proportion of CD45RA þ CCR7 þ naïve T lymphocytes. In conclusion, NET was effective in reducing trauma related PTSD symptoms and had a positive effect on the proportion of T regs cells, thus demonstrating an effect of psychotherapy on an immunological level. Yet, the shift in the proportion of naïve and memory T lymphocytes in individuals with PTSD, discussed in the literature as a correlate of premature immunosenescence, was not reversible and thus might render these patients permanently more susceptible to infectious diseases.
The probability of developing posttraumatic stress disorder (PTSD) after psychological trauma increases with the number of traumatic event types experienced (Neuner et al., 2004a; Kolassa et al., 2010) . Likewise, a doseeresponse effect of trauma exposure during childhood has been demonstrated for the development of physical health problems (Felitti et al., 1998) and impaired brain development (Teicher et al., 2012) . Furthermore, an increased risk for somatic diseases like chronic pain, cancer, cardiovascular, res piratory, gastrointestinal, and autoimmune diseases has been re ported for individuals with PTSD (Boscarino, 2004; Boscarino et al., 2010; Sareen et al., 2007) , where the poor physical health found in individuals with PTSD might be moderated by altered immune functions and inflammatory processes (Von Känel et al., 2007; Pace and Heim, 2011; Spitzer et al., 2010) .
However, linking PTSD to alterations of bulk T cell populations, representing a major branch of adaptive immunity, has been controversial: Whereas the number of circulating CD8 þ cytotoxic T cells in individuals with PTSD has been found to be mostly lower (Ironson et al., 1997; Kawamura et al., 2001; Sommershof et al., 2009) or unchanged (Altemus et al., 2006; Laudenslager et al., 1998; Vidovi c et al., 2007; Wilson et al., 1999) , the number of circulating CD3 þ T lymphocytes or CD4 þ T helper cells has been found to be lower, unchanged or even higher (Ironson et al., 1997; Laudenslager et al., 1998; Boscarino and Chang, 1999; Wilson et al., 1999; Kawamura et al., 2001; Boscarino, 2004; Vidovi c et al., 2007; Sommershof et al., 2009) . As peripheral T lymphocytes consist of a range of functionally different subpopulations, one reason for these inconsistent findings might be that changes in PTSD might be specific to certain T lymphocyte activation and differentiation states. Sommershof et al. (2009) investigated this further differ entiation of CD4 þ T helper and CD8 þ cytotoxic T cells in naïve, memory and effector cells, applying a differentiation model of T cells defined by changes in the expression of the lineage markers CD45RA and CCR7 (Hamann et al., 1999; Sallusto et al., 1999) . They found a decreased ratio of (CD45RA þ CCR7 þ ) naïve CD8 þ T cells and an increased proportion of (CD45RA À ) memory CD8 þ T cells in in dividuals with PTSD (Sommershof et al., 2009) . As a shrinking repertoire of naïve T cells may correlate with an enhanced sus ceptibility to infectious diseases (Fagnoni et al., 2000; Shen et al., 1999) , this reduction in naïve T cells represents a possible expla nation for the enhanced risk of infectious diseases in individuals with PTSD (Sommershof et al., 2009 ). Furthermore, Sommershof et al. (2009) observed a 50% decrease in the proportion of CD4
þ regulatory T cells (T reg) in individuals with PTSD. T reg cells are critical for maintaining balance in the immune system, regulating the immune response, and preventing autoim mune diseases (Vignali et al., 2008) . Decreased counts of CD4
þ T reg cells have been associated with autoim mune diseases like diabetes, multiple sclerosis, rheumatoid arthritis, psoriasis, anemia and eczema (Bennett et al., 2001; Buckner, 2010; Wildin et al., 2002) , conditions for which in dividuals with PTSD show an increased risk (Boscarino, 2004; Boscarino et al., 2010; Weisberg et al., 2002) . Given the considerable prevalence of traumatic stress, and in particular the high prevalence of PTSD in populations affected by conflict, terror and combat (Neuner et al., 2004a; Neuner and Elbert, 2007) , a highly relevant question in the context of trau matic stress and physical disease is: Can effective treatment reverse the effects of traumatic stress not only on a psychological but also on an immunological level?
Trauma focused psychotherapeutic interventions may effec tively reduce trauma related mental suffering in individuals with PTSD (Ehlers et al., 2010; Cloitre, 2009; Kleim et al., 2012; Seidler and Wagner, 2006) , and, in individuals with PTSD with comorbid borderline personality disorder (Bohus et al., 2013) or comorbid substance abuse (van Dam et al., 2013) . Moreover, it was demon strated that successful psychotherapeutic treatment also signifi cantly reduced cough, diarrhea, and fever (Neuner et al., 2008 ).
Yet, to our knowledge no study investigated the effect of psy chotherapy on T lymphocyte distribution in individuals with PTSD. So far, the impact of psychological interventions on T lymphocyte populations has mainly been examined in patients with cancer and human immunodeficiency virus (HIV), yielding mixed results. There are studies reporting a stabilization of CD4 þ T lymphocytes after psychotherapeutic interventions (Creswell et al., 2009; Petrie et al., 2004; Sherman et al., 2000) ; however, CD4 þ and CD8 þ T lymphocytes were not affected in other studies (Antoni et al., 2006; Carrico et al., 2005; Hosaka et al., 2000) . Furthermore, we know that effective psychotherapy with Narrative Exposure Therapy (NET) can reverse the increased level of DNA strand breaks observed in individuals with PTSD compared to controls (Morath et al., in press) . NET is a trauma focused treatment approach for PTSD, developed for survivors of war and torture (Schauer et al., 2011a) . Its efficacy has been proven in a number of randomized controlled trials in post conflict regions (Ertl et al., 2011; Neuner et al., 2004b) and in Europe (Hensel Dittmann et al., 2011; Robjant and Fazel, 2010) .
The present study has two aims: 1) to extend the findings by Sommershof et al. (2009) in a larger sample of individuals with PTSD, trauma exposed non PTSD subjects and non exposed con trols and 2) to investigate whether the altered T cell distribution in individuals with PTSD can be reversed by psychotherapeutic treatment with NET. Individuals with PTSD were investigated before treatment and four and 12 months after the end of therapy and T cell differentiation subsets were analyzed. We hypothesized that the NET treatment group would show an increase in the pro portions of CD45RA
Methods

Participants
Thirty four individuals with PTSD and 43 non PTSD controls were recruited through the Center of Excellence for Psycho traumatology, University of Konstanz, and public advertisements. Sixteen subjects with PTSD and 27 controls were also participants in a previous study by Sommershof et al. (2009) . After the initial screening, individuals with PTSD (age 16e47 years) e refugees (13 Africa, 21 Middle East) with a history of war and torture experi ences e were randomly assigned to either a treatment (NET group: n 17) or a waitlist control condition (WLC group: n 17). The non PTSD control group (age 16e50 years) consisted of refugees and immigrants (9 Africa, 13 Balkan, 21 Middle East) without PTSD and varying traumatic load (0e9 traumatic event types). As the number of traumatic events experienced influences T cell distri bution in a cumulative way (Sommershof et al., 2009) , we further divided the control group into a group with substantial trauma exposure (trauma exposed, n 24) and a control group with no or little trauma exposure (non trauma exposed, n 19) by median split of a traumatic load index.
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Exclusion criteria were acute infections or chronic somatic ill nesses (e.g., HIV, osteoarthrosis, autoimmune diseases) and glucocorticoid medication. Non trauma exposed control group subjects were also excluded if they met the criteria for any mental disorder according to DSM IV or reported taking psychotropic medication. Individuals with PTSD and trauma exposed controls were excluded if they met the criteria for comorbid alcohol or substance abuse and dependence or a current or past history of a psychosis according to DSM IV. The inflammation load between the time points of assessment was documented, and no severe illnesses were reported in between.
Individuals with PTSD showed no significant group differences from trauma exposed and non trauma exposed controls with respect to age and smoking behavior, but groups differed signifi cantly with respect to gender and intake of psychotropic medica tion (Table 1) . Moreover, individuals with PTSD had experienced significantly more different traumatic event types (event list of the Clinician Administered PTSD Scale [CAPS], Blake et al., 1995) , significantly more war and torture events (Vivo checklist, Schauer et al., 2011b) , and showed higher symptom scores in the CAPS, the Hamilton Depression Rating Scale (HAM D; Hamilton, 1960) and the screening for somatoform symptoms (SOMS 7; Rief and 2 Traumatic load index [(number of traumatic event types on the CAPS event list/items on the CAPS event list) þ (number of war experiences on the vivo checklist/items on the war checklist) þ (number of torture experiences on the vivo checklist/items on the torture checklist)].
Hiller, 2003) than trauma exposed and non exposed controls. Trauma exposed individuals differed significantly from non exposed controls with respect to CAPS, HAM D and SOMS 7 scores (Table 1 ). In accord with the building block effect of trau matic stress (Kolassa et al., 2010; Neuner et al., 2004a) , the trau matic load index correlated positively with PTSD symptom severity (r .65; p < .0001).
Concerning the treatment study
The NET group and the WLC did not differ significantly with respect to age, sex, ethnicity, smoking behavior or intake of psy chotropic medication, number of traumatic event types experi enced, HAM D score, or SOMS 7 score. However, the NET group showed a significantly higher PTSD symptom score (Table 1) .
Procedure
Baseline screening
All participants were screened with a clinical diagnostic inter view by trained clinical psychologists from the Center of Excellence for Psychotraumatology in Konstanz, always starting at 10 a.m. If participants were not fluent in English or German, diagnostic in terviews were completed with the help of trained interpreters. The interview started with socio demographic and health related in formation (e.g. smoking behavior, use of psychotropic medication, physical disorders). Then, the number of different traumatic event types experienced and PTSD symptom severity were assessed using the Clinician Administered PTSD Scale (CAPS; Blake et al., 1995) . In addition, the Vivo Checklist of War, Detention, and Torture Events (Schauer et al., 2011b ) was administered to assess war and torture experiences in more detail. Depressive symptoms were quantified by the Hamilton Depression Scale (HAM D; Hamilton, 1960) and somatic complaints by a shortened version of the Screening for Somatoform Symptoms (SOMS 7; Rief and Hiller, 2003) . Comorbid psychiatric disorders were assessed using the Mini International Neuropsychiatric Interview (MINI; Sheehan et al., 1998) . The same clinical diagnostic interview was repeated four and 12 months post test.
Treatment study
The trial was conducted in an ambulant setting and therapists were clinical psychologists specialized in the field of trauma and experts for narrative exposure therapy (NET). The 34 individuals with PTSD were randomly assigned to either the NET group or a WLC group. The NET group received 12 weekly treatment sessions of 90 min (Schauer et al., 2011a) . Treatment adherence was moni tored by regular supervision. The WLC group waited for about eight months without any standardized intervention. Post tests were conducted four months (t 1 ), and one year (t 2 ) after the end of NET. For the participants in the WLC group, the time spans between pre and post tests were individually matched with the NET group. For ethical reasons, the WLC group received treatment with NET after the first post test, therefore only the NET group was invited to the one year follow up. Participant flow is shown in Fig. 1 . The clini cians who performed the outcome evaluations were never the same as the clinician who performed the baseline evaluation or the psychotherapeutic intervention; moreover, the two follow up evaluations were performed by different clinicians. Diagnosticians Table 1 Socio-demographic and clinical characteristics of PTSD patients assigned to the narrative exposure therapy (NET) and the Waitlist Control (WLC) group as well as of traumaexposed individuals and control subjects. . missing immune data (n = 1 pregnant, no 1-yearfollow-up, because WLC group received psychotherapy after 8 months [ 1 Year Follow·Up } n = 5 no laboratory capacity) waiting time.
Analysis
Analysed (n = 17) Analysed (n = 17) with respect to missing values . with respect to missing values analyses were done using mixed analyses were done using mixed models procedure models procedure were blind with regard to group membership at baseline and at both post tests. The study was conducted in line with the principles of the Dedaration of Helsinki. The University of Konstanz Ethics Commit tee approved the study. All partidpants provided advance written informed consent and received 30 € remuneration for each blood drawing. Treatment with NET was provided for free. The study was registered at http://dinicaltrials.gov/ct2/show/NCT01206790.
Blood collection and lymphocyte phenotyping
Blood drawings and lymphocyte phenotyping were performed before NET started (t 0 ), four months post treatment (t 1 ), and one year post treatment (t 2 ). Blood was collected always at 10:00 a.m. in EDTA buffered tubes. Peripheral blood was sent within 1 h to the Laboratmy of Immunology. University of Konstanz, Germany, for further processing. Blood samples were coded to guarantee blind ing of the laboratory staff involved The method used for lympho cyte phenotyping was stringently equal to the method used by Sommershof et a l. (2009) .
In a first step, the total number of monocytes, granulocytes and lymphocytes were counted in whole peripheral blood samples. Lymphocytes were subdivided into B cells (CD19+), NK cells (CD16+ CDS6+), CD3+ Tcells, CD3+Co4+ T helper cells, CD3+cos+ cytotoxic T cells, and CD4+co2s+FoxP3+ Treg cells. The surface molecules CD45RA and CCR7 were used to characterize distinct T cell matu ration subsets: naiVe (CD4SRA+ CCR7+), central memory (TCM: CD45RA-CCR7+), effector memory (TEM; CD45RA-CCR7-) and CD45RA positive effector memory cells (TEMRA: CD45RA+CCR7-). Fo r a detailed description of the different classes ofT cells, their main function and their relevance to the current study, please see Table 2 .
Absolute numbers of lymphocytes were obtained using an automated hematology analyzer (XT 2000i, Sysmex, Horgen, Switzerland) . For a detailed description of lymphocyte phenotyp ing, please see Sommershof et al. (2009) .
Outcomes
Outcome measures were changes in PTSD symptom severity (CAPS score), in depressive symptoms (HAM D score), in somatic complaints (SOMS 7 score) and in (CD45RA
, and CD8 þ T cells as well
þ T reg cells four months and one year after NET.
2.5. Statistics 2.5.1. Group differences at baseline (t 0 ) Differences between groups (PTSD, trauma exposed controls, non exposed controls) in clinical characteristics and T cell distri butions were analyzed by ANOVA. As age influences T cell distri bution (Fagnoni et al., 2000; Hong et al., 2004) , age was included as a covariate in the models as also suggested by AIC (Burnham et al., 2002) . Including smoking and gender or excluding participants taking psychotropic medication did not alter results.
The KruskaleWallis test was used to analyze group differences when ANOVA residuals were not normally distributed. As we had specific hypotheses for the direction of T cell changes (reduction in the proportion of CD8 þ naïve and T reg cells), one sided independent t tests or the WilcoxoneManneWhitney test were used for post hoc analyses for these variables. Correlations were analyzed with the Kendall tau rank correlation.
Treatment study
Linear mixed models were used to analyze changes in clinical characteristics and lymphocyte differentiations from t 0 to t 1 . Age was included as covariate for T cell analysis. Since residuals in the model of CD3 þ total T cells and CD8 þ memory T cells were not normally distributed, data were retested with a logarithmized data set and results remained stable. Changes from t 0 to t 1 and t 2 within the NET group were analyzed by linear mixed models and paired t tests for post hoc comparisons. Treatment effect sizes were calcu lated by Hedges' g (Hedges, 1981) .
Results
The effect of traumatic stress and PTSD on T cell distribution at t 0
There was no difference in the absolute cell number of lym phocytes (c 2 .72; p .70) between individuals with PTSD (me dian 1939, range 1249e2800), trauma exposed individuals (median 1960, range 1301e2938), and non traumatized controls (median 1815, range 1308e2965), but the percentage of total CD3 þ T cells was significantly reduced in individuals with PTSD compared to non traumatized controls (Table 3) . Extending the results of Sommershof et al. (2009) , we found a significant main effect for Group with respect to the percentage of nai've cos+ T cells (F(2.68l 3.72; p .03), with post hoc tests revealing significant group differences between individuals with PTSO and non traumatized controls ( t(27.0) 2.04; p .04; one sided) and be tween trauma exposed subjects and controls ( t(3t.5) 1.S7; p .03; one sided), but not between individuals with PTSO and trauma exposed controls ( t(3s.9) .04; p .49; one sided; see Table 3 ). Again, there was a significantly increased percentage of memory e 8 "'
... Table 3 ). The number of different traumatic event types experienced correlated negatively with the percentage of naïve CD8 þ T cells (r .24; p .04), i.e. higher values in traumatic load as measured by the traumatic load index were associated with a stronger reduction in naïve CD8 þ T cells.
cos+ T cells in individuals with
Effects of NET on T cell distribution
Four months after treatment, PTSD symptom severity (CAPS sum score) had declined significantly in the NET compared to the WLC group (Time Â Treatment F (1,32) 16.90; p .0003). The effect size of treatment in the NET group was large (Hedges' g 1.61). Post hoc tests showed a significant decline in symptom severity in the NET group from t 0 to t 1 (t (16) 5.99; p < .0001), whereas symptom severity remained stable in the WLC group. At t 2 , the NET group showed an even greater decline in symptoms (Time F (1, 32) 32.04; p .0001) with an effect size of Hedges' g 1.96 from t 0 to t 2 (Fig. 2a) . NET also improved somatic symptoms, as measured with the SOMS 7, in the treatment but not in the WLC group (Time Â Treatment, F (1,31) 6.19; p .02; Fig. 2b ). However, depressive symptoms (HAM D) were not significantly improved in the NET compared to the WLC group (Time Â Treatment, F (1,32) .89; p .35, see Table 4 ). Against our hypothesis, there was no treatment specific in crease in the percentage of naïve CD8 þ T cells from t 0 to t 1 (Time Â Treatment F (1, 25) .05; p .82, Table 4 and Fig. 2c ), or from t 0 to t 2 within the PTSD group (Time F (1, 21) 2.17; p .16). Furthermore, there were no treatment specific alterations in the percentage of memory CD8 þ T cells in the NET, compared to the WLC group (Time Â Treatment F (1,25) .60; p .45) and no sig nificant changes in the percentage of memory CD8 þ T cells over time (Time F (1, 21) .28; p .60) within the NET group (see Fig. 2d ).
With respect to the percentage of T reg cells, we found no Time Â Treatment interaction (F (1,23) 3.06; p .09) from t 0 to t 1 (Table 4) , and no significant increase in the percentage of T reg over time (Time F (1, 20) 3.40; p .08) within the NET group. However there was a significant time effect from t 1 to t 2 within the NET group (t (6) 2.37; p .05). Since the NET and the WLC group differed significantly at t 0 in T reg cell counts (t (22.7) 2.24; p .04), which could have induced spurious effects through regression to the mean, we performed an additional analysis excluding the two subjects with the highest percentage of T regs in the NET and the two subjects with the lowest percentage of T regs in the WLC group, parallelizing groups with respect to T reg cell counts (t (20.6) 1.32; p .20). Again, there was no Time Â Treatment interaction from t 0 to t 1 (F (1, 19) .85; p .37), but the NET group showed a significant increase in T regs over time (Time F (1, 17) 8.06; p .01; Fig. 2e ). Post hoc tests revealed a significant increase from t 0 to t 2 (t (7) 1.45; p .05) and from t 1 to t 2 (t (5) 2.56; p .05), but not from t 0 to t 1 . Furthermore, there was a marginally significant but large positive association be tween PTSD symptom reduction from t 0 to t 2 and the increase of T regs from t 0 to t 2 (r .75; p .09). No treatment specific alterations were found for the other T cell subtypes investigated (see Table 4 ) except for the total percentage of CD4 þ T cells, increasing significantly from t 0 to t 2 within the NET group (F (1, 22) 6.53; p .02). 
Discussion
Extending the findings of Sommershof et al. (2009) in a larger sample, we found a decreased proportion of (CD45RA
cells at baseline in individuals with PTSD compared to controls with no or little trauma exposure. Moreover, trauma exposed non PTSD subjects showed a significantly lower proportion of naïve CD8 þ T cells than non exposed controls, and the number of traumatic event types experienced was significantly negatively correlated with the percentage of naïve CD8 þ T cells, indicating a cumulative effect of exposure to traumatic stressors. As we found no differ ences between non PTSD subjects with or without trauma expo sure with respect to T reg cells, we propose that the reduction of naïve CD8 þ T cells is a consequence of trauma burden rather than an explicit feature of PTSD, whereas alterations in regulatory T cells seem to be specifically associated with the chronic stress experi enced by individuals with PTSD. The decrease in naïve and the increase in memory CD8 þ T cells in individuals with PTSD are in accordance with a T lymphocyte distribution typical for older in dividuals (Dorshkind et al., 2009; Fagnoni et al., 2000; Hong et al., 2004) . Therefore, the alterations in T lymphocyte distributions in individuals with PTSD might indicate a process of premature immunosenescence, which is in line with previous findings showing that psychological stress is associated with immunological aging (Bosch et al., 2009; Epel et al., 2004; Kiecolt Glaser et al., 2003) . This immunosenescence might be related to a higher wear and tear of the immune system, as the consequences of chronic/ traumatic stress may be reflected in a blunted immunity that in creases the probability for diseases and associated inflammation responses. NET led to reduced PTSD symptoms four months after treatment and even further in the one year follow up and improved somatic complaints such as headache, diarrhea, nausea or unspecific chronic pain conditions e consistent with the reported benefits of NET on physical health conditions (Neuner et al., 2008) . Depressive symptoms did not improve through NET. The reduced proportion of CD8 þ CD45RA þ CCR7 þ naïve T lymphocytes in PTSD did not increase through treatment, suggesting that the shift in the proportion of naïve and memory T lymphocytes in individuals with PTSD is not reversible and thus might render these patients permanently more susceptible to infectious diseases (Fagnoni et al., 2000; Shen et al., 1999) . In accordance with our outcomes, CD8 þ T lymphocytes have been reported to be stable over time and not affected by psycho therapeutic interventions in cancer or HIV patients (Carrico et al., 2005; Hosaka et al., 2000) . However, the reduced proportion of CD4
cells increased with symptom improvement in the NET group at the one year follow up when comparing subgroups matched for baseline cell numbers. T reg cells, originally termed suppressor T cells, are essential for controlling immune responses and main taining self tolerance by inhibiting autoreactive T cells. A decrease in number or function of peripheral T reg cells has been associated with the development of autoimmune diseases, such us multiple sclerosis, asthma, type 1 diabetes, psoriasis, and rheumatoid arthritis (Costantino et al., 2008) . Interestingly, antidepressant medication in individuals suffering from a depressive episode improved not only depressive symptoms but increased also T reg (CD4 þ CD25 hi ) cell counts (Himmerich et al., 2010) . Moreover, autoimmune diseases seem to react favorably to psychological in terventions (Carlson, 2012) . Finally, therapeutic intervention studies focusing on selective enhancement of antigen specific T reg populations in vitro or in vivo have become a promising target for novel immunotherapeutic approaches in order to reduce or prevent immune mediated pathologies in human autoimmune diseases (Cools et al., 2007) . Considering the fundamental role of T reg cells in controlling both immunity and tolerance, it will be important to establish whether restoration of T reg numbers by psychothera peutic treatment can prevent the induction of autoimmune pa thology or even reverse established disease in PTSD patients.
Limiting factors for the interpretation of our data are: 1) the lack of a one year follow up in the WLC group; 2) missing information about T cell distributions in healthy controls four months and one year after the baseline assessment. Yet, in a study with healthy university students, T cell subpopulations remained stable over a period of 3 months free of examinations (Hamuni et al., submitted for publication); 3) The intake of psychotropic medication in about 40% of the individuals with PTSD, which was, however, equally distributed across groups before and after treatment and thus should not be able to be the factor accounting for the observed effects. 4) The relatively small sample size; and 5) the varied eth nicities of study participants. However, since treatment with NET has been shown to be effective in various populations all over the world (Robjant and Fazel, 2010) , we can assume that there is no cultural difference in the biological processing of traumatic stress; 5) We investigated a severely traumatized PTSD sample with high symptom scores, allowing us to study consequences of extreme stress. However, treatment with NET in such an affected sample resulted only in a significant reduction of symptoms, but not in a full recovery from PTSD (58.8% of the NET group still fulfilled PTSD criteria four months post test). Moreover, individuals with PTSD continued to live under stressful life circumstances (e.g. 88.2% of the individuals with PTSD have an insecure asylum status and fear deportation). These factors might have precluded stronger therapy effects concerning T cell maturations subsets and might also explain the persistence of depressive symptoms.
In conclusion, some biological consequences of traumatic stress, such as the shift in the proportion of naïve and memory T lym phocytes, seem to not be reversible through trauma focused psy chotherapy, while other consequences such as the reduction of T reg cells similar to the increased level of DNA damage in peripheral blood mononuclear cells of PTSD patients seem to be alterable through therapy (Morath et al., in press ). Further studies on the long term effects of psychotherapy on the immune system are necessary. If the results of this study can be replicated, this would underline the need for effective treatment of PTSD in trauma affected populations to prevent the manifestation of secondary physical diseases in the long run.
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